TY - JOUR
T1 - Mucosal vaccine delivery
T2 - Current state and a pediatric perspective
AU - Shakya, Akhilesh Kumar
AU - Chowdhury, Mohammed Y.E.
AU - Tao, Wenqian
AU - Gill, Harvinder Singh
N1 - Funding Information:
We acknowledge the support by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health (NIH) under Award Number DP2HD075691 , National Institute of Health 1R03DE021667-01A1 and R21AI099575 to HSG, and Defense Advanced Research Projects Agency (DARPA) — Young Faculty Award under grant number N66001-12-1-4251 to HSG.
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/10/28
Y1 - 2016/10/28
N2 - Most childhood infections occur via the mucosal surfaces, however, parenterally delivered vaccines are unable to induce protective immunity at these surfaces. In contrast, delivery of vaccines via the mucosal routes can allow antigens to interact with the mucosa-associated lymphoid tissue (MALT) to induce both mucosal and systemic immunity. The induced mucosal immunity can neutralize the pathogen on the mucosal surface before it can cause infection. In addition to reinforcing the defense at mucosal surfaces, mucosal vaccination is also expected to be needle-free, which can eliminate pain and the fear of vaccination. Thus, mucosal vaccination is highly appealing, especially for the pediatric population. However, vaccine delivery across mucosal surfaces is challenging because of the different barriers that naturally exist at the various mucosal surfaces to keep the pathogens out. There have been significant developments in delivery systems for mucosal vaccination. In this review we provide an introduction to the MALT, highlight barriers to vaccine delivery at different mucosal surfaces, discuss different approaches that have been investigated for vaccine delivery across mucosal surfaces, and conclude with an assessment of perspectives for mucosal vaccination in the context of the pediatric population.
AB - Most childhood infections occur via the mucosal surfaces, however, parenterally delivered vaccines are unable to induce protective immunity at these surfaces. In contrast, delivery of vaccines via the mucosal routes can allow antigens to interact with the mucosa-associated lymphoid tissue (MALT) to induce both mucosal and systemic immunity. The induced mucosal immunity can neutralize the pathogen on the mucosal surface before it can cause infection. In addition to reinforcing the defense at mucosal surfaces, mucosal vaccination is also expected to be needle-free, which can eliminate pain and the fear of vaccination. Thus, mucosal vaccination is highly appealing, especially for the pediatric population. However, vaccine delivery across mucosal surfaces is challenging because of the different barriers that naturally exist at the various mucosal surfaces to keep the pathogens out. There have been significant developments in delivery systems for mucosal vaccination. In this review we provide an introduction to the MALT, highlight barriers to vaccine delivery at different mucosal surfaces, discuss different approaches that have been investigated for vaccine delivery across mucosal surfaces, and conclude with an assessment of perspectives for mucosal vaccination in the context of the pediatric population.
KW - Intranasal vaccination
KW - Mucosal vaccination
KW - Nasal vaccination
KW - Oral cavity vaccination
KW - Oral vaccination
KW - Pollen grains
KW - Skin vaccination
UR - http://www.scopus.com/inward/record.url?scp=84964371820&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2016.02.014
DO - 10.1016/j.jconrel.2016.02.014
M3 - Article
C2 - 26860287
AN - SCOPUS:84964371820
SN - 0168-3659
VL - 240
SP - 394
EP - 413
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -